Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/22/2005WO2005087732A1 Biphenyl compounds useful as muscarinic receptor antagonists
09/22/2005WO2005087729A1 5-hydroxyindole-3-carboxylates derivatives and their use
09/22/2005WO2005087728A1 Resistance-repellent retroviral protease inhibitors
09/22/2005WO2005087727A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005WO2005087726A1 Novel aryl-containing 5-acylindolinones, the production thereof and their use as medicaments
09/22/2005WO2005087724A2 Sulphonylpyrroles as hdac inhibitors
09/22/2005WO2005087722A1 Diphenylmethyl compounds useful as muscarinic receptor antagonists
09/22/2005WO2005087714A2 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
09/22/2005WO2005087713A1 Amide compound, pharmaceutical composition and rxr function control agent
09/22/2005WO2005087710A1 Aminophenylpropanoic acid derivative
09/22/2005WO2005087708A1 Phenyl indan derivatives
09/22/2005WO2005087701A1 Novel 2-(α -n-pentanonyl)benzoates, their preparation and use
09/22/2005WO2005087289A1 Adhesion preventive material
09/22/2005WO2005087288A1 Medicinal preparation for angiogenesis
09/22/2005WO2005087270A1 Anti-vaginitis compositions comprising a triazole
09/22/2005WO2005087269A1 Method of inhibiting tumor proliferation
09/22/2005WO2005087268A1 Axon regeneration promoter
09/22/2005WO2005087267A1 Remedies for prostatic hypertrophy
09/22/2005WO2005087266A1 Combination therapy for inhibition of platelet aggregation
09/22/2005WO2005087265A1 Antineoplastic combinations of cci-779 and rituximab
09/22/2005WO2005087264A1 Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
09/22/2005WO2005087260A1 Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
09/22/2005WO2005087253A2 Interferon-beta for anti-virus therapy for respiratory diseases
09/22/2005WO2005087242A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
09/22/2005WO2005087241A1 Infection-controlling agent for livestock, poultry or fish
09/22/2005WO2005087238A2 Method for stimulating the immune, inflammatory or neuroprotective response
09/22/2005WO2005087237A1 Fasudil-containing preparation and method of improving stability thereof
09/22/2005WO2005087236A1 Novel m3 muscarinic acetylcholine receptor antagonists
09/22/2005WO2005087235A1 Pyrrolidine compounds
09/22/2005WO2005087234A1 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
09/22/2005WO2005087233A1 Perhexilin for treating chronic heart failure
09/22/2005WO2005087232A1 Bicyclic modulators of androgen receptor function
09/22/2005WO2005087231A1 Solifenacin-containing composition
09/22/2005WO2005087230A1 Solid pharmaceutical preparation containing sparingly water-soluble drug
09/22/2005WO2005087229A1 Ion channel modulators
09/22/2005WO2005087228A1 Ion channel modulators
09/22/2005WO2005087227A1 Arylalkylamino-substituted quinazoline analogues
09/22/2005WO2005087226A1 Cadasil treatment with cholinesterase inhibitors
09/22/2005WO2005087225A1 Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
09/22/2005WO2005087224A1 Composition for stabilizing epigallocatechin gallate (egcg) in water phase and preparation method thereof
09/22/2005WO2005087223A1 ANDROGRAPHOLIDE AND ANALOGUES AS INHIBITORS OF TNFα AND IL-1βEXPRESSION
09/22/2005WO2005087222A1 C7 lactyloxy-substituted taxanes
09/22/2005WO2005087221A1 Biodegradable biocompatible implant and method of manufacturing same
09/22/2005WO2005087220A1 Antiwrinkling preparation
09/22/2005WO2005087219A1 Memory fixation accelerator
09/22/2005WO2005087218A1 Dietary supplementation with stoichiometrically specific potassium magnesium citrate
09/22/2005WO2005087217A1 Compositions and methods for modulating interaction between polypeptides
09/22/2005WO2005087216A2 Treatment of anaemic conditions by inhibition of erythrocyte apoptosis
09/22/2005WO2005087215A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005WO2005087214A1 Methods for treating multiple sclerosis and pharmaceutical compositions therefor
09/22/2005WO2005087213A1 Combination of deramciclane and opoids as analgesics
09/22/2005WO2005087212A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
09/22/2005WO2005087211A1 Anti-parasitic compounds and methods of their use
09/22/2005WO2005087210A2 Prevention of retinopathy by inhibition of the visual cycle
09/22/2005WO2005087209A1 Antiviral composition comprising p-menthane-3, 8-diol
09/22/2005WO2005087208A2 Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
09/22/2005WO2005087207A1 Compositions and methods for the treatment of depression and other affective disorders
09/22/2005WO2005087206A2 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
09/22/2005WO2005087205A1 Process for producing medicine
09/22/2005WO2005087204A1 Bioavailable solid dosage forms of metaxalone
09/22/2005WO2005087200A1 Particulate plant sterol compositions
09/22/2005WO2005087199A2 Stabilised supersaturated solid solutions of steroidal drugs
09/22/2005WO2005087198A1 Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
09/22/2005WO2005087194A1 Compositions comprising drospirenone molecularly dispersed
09/22/2005WO2005087192A2 Salmeterol inhalation formulations
09/22/2005WO2005087182A1 Functional powders
09/22/2005WO2005087025A1 Composition; use of a composition and a method for treating obesity
09/22/2005WO2005087023A1 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome
09/22/2005WO2005087017A2 Compositions comprising reverse isomers of conjugated linoleic acid
09/22/2005WO2005086971A2 Anti-metastatic ability of mibefradil and gadolinium
09/22/2005WO2005086960A2 Narcotic-nsaid ion pairs
09/22/2005WO2005086954A2 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
09/22/2005WO2005086944A2 Combination therapies using leptomycin b
09/22/2005WO2005086941A2 Process and composition for teating viral infections
09/22/2005WO2005086904A2 Therapeutic modulation of ppar (gamma) activity
09/22/2005WO2005086898A2 Inhibitors of histone deacetylase
09/22/2005WO2005086895A2 Ion channel modulators
09/22/2005WO2005086871A2 Compounds, compositions and methods for inhibiting or treating hiv-1
09/22/2005WO2005086808A2 NOVEL DICATIONIC IMIDAZO[1,2-a]PYRIDINES AND 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2a]PYRIDINES AS ANTIPROTOZOAL AGENTS
09/22/2005WO2005086768A2 Enhanced production of functional proteins from defective genes
09/22/2005WO2005086763A2 Stable injectable compositions
09/22/2005WO2005086735A2 Novel bicyclic compounds as modulators of androgen receptor function and method
09/22/2005WO2005086697A2 Materials for medical implants and occlusive devices
09/22/2005WO2005086694A2 Occlusive biomedical devices, punctum plugs, and methods of use thereof
09/22/2005WO2005086656A2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
09/22/2005WO2005086641A2 Anti-infectious hydrogel compositions
09/22/2005WO2005086638A2 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
09/22/2005WO2005086619A2 Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
09/22/2005WO2005079756A3 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
09/22/2005WO2005074947A3 Anti-viral pharmaceutical compositions
09/22/2005WO2005072736A3 Stable gabapentin compositions
09/22/2005WO2005072681A3 Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
09/22/2005WO2005069855A3 Modulators of angiogenesis
09/22/2005WO2005067962A3 Composition derived from milk goat comprising growth factors and oligosaccharides
09/22/2005WO2005065069A3 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
09/22/2005WO2005063234A3 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung diseases
09/22/2005WO2005063232A8 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
09/22/2005WO2005063195A3 Compositions comprising vitamins and/or derivatives thereof stabilised with olea europea extract and/or ionene polymers
09/22/2005WO2005062722A3 Fexofenadine containing pharmaceutical formulation
09/22/2005WO2005058235A3 Methods using sulodexide for the treatment of bladder disease
1 ... 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 ... 7860